



ITW
Docket No. 100-8024C/C1/D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Sedrani et al.

APPLICATION NO: 09/585,743

FILED: June 2, 2000

FOR: Rapamycin Assay

Art Unit: 1641

Examiner: HAQ, SHAFIQU L

Confirmation No. 7135

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT

Dear Sir:

Dear Sir:

Please find enclosed a certified copy of the UK priority document, patent application No: 94307491.2

If there are any remaining issues or the Examiner believes that a telephone conference with the Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617)-871-8469.

Applicants believe that no fees are due with this filing. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936

Date: June 14, 2011

Christine McCormack
Attorney for Applicant
Reg. No. 61,331

(617) 871-8486